IDH2 and diffuse large B-cell lymphoma: Using unsupervised ML models, Hemmingsen et al. have revealed that patients with low expression of STING1 and IDH2 are at higher odds of progressing to diffuse large B-cell lymphoma (DLBCL) [25].